Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15

Cancer Research

Volumn 60, Issue 13, 2000, Pages 3577-3583

  Kobayashi, Hisataka ^a   Carrasquillo, Jorge A ^a,c   Paik, Chang H ^a   Waldmann, Thomas A ^b   Tagaya, Yutaka ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG TARGETING; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIODINATION; TISSUE DISTRIBUTION;

ALPHA-MACROGLOBULINS; ANIMALS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; IODINE RADIOISOTOPES; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034234925     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Rubin, J. T. Interleukin-2: its rationale and role in the treatment of patients with cancer. Cancer Treat. Res., 80: 83-105, 1995.
2. Waldmann, T. A. The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-1-associated disorders. J. Acquired Immune Defic. Syndr. Hum. Retrovirol., 13 (Suppl. 1): S179-S185, 1996.
3. Sneller, M. C. Consensus symposium on combined antiviral therapy: overview of interferon and IL-2 combinations for the treatment of HIV infection. Antiviral Res., 29: 105-109, 1996.
4. Tafuto, S., Silvestri, I., D'Andrea, P., Ronga, D., and Abate, G. Interleukin-6: biological features and clinical implications. J. Biol. Regul. Homeost. Agents, 8: 1-8, 1994.
5. Visani, G., and Manfroi, S. G-CSF in the biology and treatment of acute myeloid leukemias. Leuk. Lymphoma, 18: 423-428, 1995.
6. Zumkeller, W., and Schofield, P. N. Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res., 15: 343-348, 1995.
7. Fraker, D. L., and Alexander, H. R. The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results. Melanoma Res., 4 (Suppl. 1): 27-29, 1994.
8. LeMaistre, C. F., Craig, F. E., Meneghetti, C., McMullin, B., Parker, K., Reuben, J., Boldt, D. H., Rosenblum, M., and Woodworth, T. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res., 53: 3930-3934, 1993.
9. LeMaistre, C. F., Saleh, M. N., Kuzel, T. M., Foss, F., Platanias, L. C., Schwartz, G., Ratain, M., Rook, A., Freytes, C. O., Craig, F., Reuben, J., and Nichols, J. C. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lyrnphomas expressing the receptor for interleukin-2. Blood, 91: 399-405, 1998.
10. LeMaistre, C. F., Meneghetti, C., Rosenblum, M., Reuben, J., Parker, K., Shaw, J., Deisseroth, A., Woodworth, T., and Parkinson, D. R. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood, 79: 2547-2554, 1992.
11. Rozemuller, H., Rombouts, W. J., Touw, I. P., FitzGerald, D. J., Kreitman, R. J., Pastan, I., Hagenbeek, A., and Martens, A. C. Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model. Leukemia (Baltimore), 10: 1796-1803, 1996.
12. Husain, S. R., Behari, N., Kreitman, R. J., Pastan, I., and Puri, R. K. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res., 58: 3649-3653, 1998.
13. Sweeney, E. B., Foss, F. M., Murphy, J. R., and vanderSpek, J. C. Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells. Bioconjug. Chem., 9: 201-207, 1998.
14. Cai, J., Zheng, T., Murphy, J., Waters, C. A., Lin, G. Y., and Gill, P. S. IL-4R expression in AIDS-KS cells and response to rhIL-4 and IL-4 toxin (DAB389-IL-4). Investig. New Drugs, 15: 279-287, 1997.
15. Kreitman, R. J., Puri, R. K., Leland, P., Lee, B., and Pastan, I. Site-specific conjugation to inlerleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity. Biochemistry, 33: 11637-11644, 1994.
16. Bamford, R. N., Grant, A. J., Burton, J. D., Peters, C., Kurys, G., Goldman, C. K., Brennan, J., Roessler, E., and Waldmann, T. A. The incerleukin (IL) 2 receptor β chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA, 91: 4940-4944, 1994.
17. Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., Johnson, L., Alderson, M. R., Watson, J. D., Anderson, D. M., and Giri, J. G. Cloning of a T-cell growth-factor that interacts with the β-chain of the interleukin-2 receptor. Science (Washington DC), 264: 965-968, 1994.
18. Tagaya, Y., Bamford, R. N., DeFilippis, A. P., and Waldmann, T. A. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity, 4: 329-336, 1996.
19. Giri, J. G., Kumaki, S., Ahdieh, M., Friend, D. J., Loomis, A., Shanebeck, K., Dubose, R., Cosman, D., Park, L. S., and Anderson, D. M. Identification and cloning of a novel 11-15 binding-protein that is structurally related to the α-chain of the IL-2 receptor. EMBO J., 14: 3654-3663, 1995.
20. Sabe, H., Kondo, S., Shimizu, A., Tagaya, Y., Yodoi, J., Kobayashi, N., Hatanaka, M., Matsunami, N., Maeda, M., and Noma, T. Properties of human interleukin-2 receptors expressed on non-lymphoid cells by cDNA transfection. Mol. Biol. Med., 2: 379-396, 1984.
21. Katsanis, E., Xu, Z., Panoskaltsis-Mortari, A., Weisdorf, D. J., Widmer, M. B., and Blazar, B. R. IL-15 administration following syngeneic bone marrow transplantation prolongs survival of lymphoma bearing mice. Transplantation, 62: 872-875, 1996.
22. Coligan, John E. (ed.). Current Protocols in Immunology, Vol. 1, p. 6.0. New York: Greene Publishing Associates and Wiley-Interscience, 1991.
23. Kobayashi, H., Sakahara, H., Saga, T., Hosono, M., Shirato, M., Kanda, H., Ishibashi, K., Watanabe, T., Endo, K., Ishiwata, I., and Konishi, J. A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer. Cancer Immunol. Immunother., 37: 143-149, 1993.
24. Kreitman, R. J., and Pastan, I. Recombinant single-chain immunotoxins against T and B cell leukemias. Leuk. Lymphoma, 13: 1-10, 1994.
25. Kobayashi, H., Tagaya, Y., Han, E-S., Kim, I. S., Le, N., Paik, C. H., Pastan, I., Nelson, D. L., Waldmann, T. A., and Carrasquillo, J. A. Use of an Antibody against the soluble interleukin-2 receptor a subunit Can modulate the stability and biodistribution of interleukin-2. Cytokine, 11: 1065-1075, 1999.
26. Dillman, R. O. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother., 9: 183-209, 1994.
27. 123I-interleukin-2. Labelling procedure and animal studies. Nucl. Med. Commun., 13: 713-722, 1992.
28. Donohue, J. H., and Rosenberg, S. A. The fate of interleukin-2 after in vivo administration. J. Immunol., 130: 2203-2208, 1983.
29. James, K. Interactions between cytokines and α2-macroglobulin. Immunol. Today, 11: 163-166, 1990.
30. Borth, W., and Teodorescu, M. Inactivation of human interleukin-2 (IL-2) by α2-macroglobulin-trypsin complexes. Immunology, 57: 367-371, 1986.
31. Lodolce, J. P., Boone, D. L., Chai, S., Swain, R. E., Dassopoulos, T., Trettin, S., and Ma, A. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity, 9: 669-676, 1998.
32. Tagaya, Y., Burton, J. D., Miyamoto, Y., and Waldmann, T. A. Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells. EMBO J., 15: 4928-4939, 1996.
33. Katsanis, E., Xu, Z., Panoskaltsis Mortari, A., Hasz, D. E., Weisdorf, D. J., Widmer, M. B., and Blazar, B. R. IL-15 administration following syngeneic murine bone marrow transplantation (BMT) for lymphoma improves survival and has decreased toxicity when compared to IL-2. Blood, 86: 2272-2272, 1995.